**Letter to the Editor (Case report)**

**RHEUMATOLOGY ADVANCES IN PRACTICE**

Rheumatology Advances in Practice 2022:00:1–3  
http://doi.org/10.1093/rap/rkac032  
Advance Access Publication 13 May 2022

**Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient**

**Key message**

- Awareness of emergence of tuberculosis should also include patients treated with Janus kinase inhibitors.

**Dear Editor,**  
We report on a 68-year-old Caucasian male with a 6-year history of PsA who developed pulmonary and lymph node tuberculosis (TB) 6 months after initiation of treatment with the Janus kinase 1 (JAK1) inhibitor upadacitinib. Before upadacitinib, he had been treated with MTX for 2 years, secukinumab for 10 months, ustekinumab for 6 months and infliximab for 12 months without success. The time interval between the last infliximab dose and the start of treatment with upadacitinib was 18 months. While being well controlled for his PsA with upadacitinib without concomitant synthetic DMARD, he presented with a rapidly and steadily growing tumour on the left side of his neck, which emerged within 2 weeks. Other symptoms, such as chills, fever, dyspnoea, cough, weight loss or night sweats, were absent. The patient was admitted to our ward for further work-up. On physical examination, he was haemodynamically stable and presented with a prominent lymph node on the left side of the neck. No other abnormalities were found. A chest radiograph and a chest/neck CT scan revealed a round consolidation in the left lung (Fig. 1B and C) and an enlarged lymph node in the left side of his neck (Fig. 1D). Laboratory data upon admission revealed normal white blood cell counts, mild anaemia (haemoglobin: 11.8–15.5 g/dl), elevated CRP (< 5 mg/l) and elevated ESR (< 20 mm/h). Serological tests for HIV, HBV and HBC were negative. IFN-γ release assay (IGRA) and nested PCR for *Mycobacterium tuberculosis* complex in sputum were negative. Bronchoscopy, microscopy and culture of bronchoalveolar lavage fluid confirmed the presence of *M. tuberculosis*.

Our patient had no previous history of TB, close contact with anyone with TB, or travel to a TB-endemic area in the past decade. The screenings for latent TB using IGRA and chest radiographs were negative each time he was started on a new PsA treatment regimen. His last negative IGRA and normal chest radiograph were immediately before starting upadacitinib (Fig. 1A). After lymph node excisional biopsy that also confirmed TB, we started a quadruple therapy with ethambutol, rifampicin, isoniazid and pyrazinamide at standard dosages, because there was no evidence of genotypic resistance associated with the therapy. Owing to the strong interaction via CYP3A4 between tuberculostatic drugs, upadacitinib was stopped. After 4 months of treatment, *M. tuberculosis* complex microscopy and culture in sputum were negative, and therapy was reduced to a combination of rifampicin and isoniazid. During TB treatment, the patient flared, with development of synovitis, morning stiffness, skin lesions and persistent nail psoriasis. We decided to re-administer upadacitinib after 5 months of TB treatment, because of prior good skin/joint disease control and the poor response to other biological DMARDs, under tight clinical and laboratory control, with rapid improvement of symptoms.

The diagnosis of TB remains challenging in the settings of older age, biological treatment and/or altered immune response. Anti-TNF antibodies are associated with an increased risk for reactivation of latent TB. Currently, no data regarding TB reactivation exist for upadacitinib [1]. Long-term safety data for tofacitinib (JAK1/3 inhibitor) [2, 3] and baricitinib (JAK1/2 inhibitor) [4] in RA revealed TB cases, mostly in endemic areas [5, 6]. To date, the safety profile of JAK inhibitors is characterized by an increased risk of herpes zoster infection, but not TB [5]. It has been hypothesized, based on other JAK inhibitors, such as ruxolitinib (JAK2), indicated for myelofibrosis and polycythaemia vera, that they might increase the risk of TB infections, through down-regulating Th-1 responses and production of IFN-γ, a key cytokine involved in protective immunity against *M. tuberculosis* [7].

In this case, TB started during upadacitinib treatment. It is unclear whether there is a causal relationship between TB and the treatment. However, there was no evidence for a new infection with TB, although it cannot be ruled out completely. Reactivation of TB seems more likely in this case, despite negative IGRA. False-negative IGRA tests have been described to occur during immune-modulatory treatment of arthritis [8]. This case highlights the limitations of screening for TB and the possibility that TB can complicate JAK inhibition. Tuberculostatic treatment, however, successfully contained the infection, also allowing the treatment with the JAK inhibitor upadacitinib to be restarted, showing that this complication could be managed well. Nonetheless, awareness of the emergence of TB should also include patients treated with JAK inhibitors.

**Acknowledgements**

The authors thank Louis Schuster for his technical assistance.
L.V.-M., A.K., J.W. and B.M. contributed to the treatment design and patient management, L.V.-M. and A.K. conceived the presented idea and wrote the paper with input from B.M and G.S. All authors listed have made a substantial, direct and intellectual contribution to the work and approved it for publication.

Funding: No financial support was received from any funding bodies in the public or commercial sectors to carry out the work described in this manuscript.

Disclosure statement: The authors have declared no conflicts of interest.

Consent and ethics: Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article. We received standard ethics approval #157_20 B and the TARDA database.

Data availability statement

The data supporting the conclusions of this article will be made available by the authors, without undue reservation.

References

1 McInnes IB, Anderson JK, Magrey M et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med 2021;384:1227–39.

2 Cohen SB, Tanaka Y, Mariette X et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from

Fig. 1 Lymph node and pulmonary tuberculosis during upadacitinib treatment

(A) Tumour in the left side of the neck. (B and C) Consolidation in the left lung in CT scan. (D) Nodule in the left side of the neck in CT scan.
the global clinical trials. Ann Rheum Dis 2017;76:1253–62.

3 Winthrop KL, Park SH, Gul A et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1133–8.

4 Smolen JS, Genovese MC, Takeuchi T et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol 2019;46:7–18.

5 Cantini F, Blandizzi C, Niccoli L, Petrone L, Goletti D. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf 2020;19:861–72.

6 Genovese MC, Fleischmann R, Combe B et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 2018;391:2513–24.

7 Coltro G, Vannucchi AM. The safety of JAK kinase inhibitors for the treatment of myelofibrosis. Expert Opin Drug Saf 2021;20:139–54.

8 Cantini F, Nannini C, Niccoli L et al. Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics. Mediators Inflamm 2017;2017:8909834.